Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23.

IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES
Diogo Fp Marques, Dory Kovacs, Miguel-Angel Sanchez-Ruiz, Ana Paula Rodrigues, Ausenda Machado, Clara Mazagatos, Susana Monge, Lisa Domegan, Joan O'Donnell, Mariette Hooiveld, Hanne-Dorthe Emborg, Baltazar Nunes, Carlos Carvalho, Angela Mc Rose
{"title":"Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23.","authors":"Diogo Fp Marques, Dory Kovacs, Miguel-Angel Sanchez-Ruiz, Ana Paula Rodrigues, Ausenda Machado, Clara Mazagatos, Susana Monge, Lisa Domegan, Joan O'Donnell, Mariette Hooiveld, Hanne-Dorthe Emborg, Baltazar Nunes, Carlos Carvalho, Angela Mc Rose","doi":"10.2807/1560-7917.ES.2025.30.20.2400655","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundBetween 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels.AimWe evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance.MethodsWe analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats.ResultsThirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat.ConclusionsSARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 20","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.20.2400655","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundBetween 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels.AimWe evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance.MethodsWe analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats.ResultsThirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat.ConclusionsSARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.

欧洲严重急性呼吸道感染(SARI)监测评价,27个欧洲国家,2022/23。
在2020年至2023年期间,ECDC通过加强严重急性呼吸道感染(SARI)监测来监测趋势、发现意外事件、评估公共卫生干预措施、确定风险因素和支持疫苗有效性研究,为30个欧盟/欧洲经济区中的21个国家和6个西巴尔干国家提供了支持。各国采用不同的战略实施了严重急性呼吸道感染监测,并在国家/欧洲层面报告了数据。AimWe评估了欧洲水平的SARI监测,并提供了实现目标和改进关键属性绩效的建议。方法对2022/23年的监测数据进行分析,以确保其完整性。我们针对国家级代表进行了问卷调查,以评估监测属性(满足目标、有用性、可接受性、及时性、代表性),并确定优势、劣势、机会和威胁。结果13个国家(13/27)报告了欧洲水平的数据。数据显示总体上完整性良好,但各国之间存在差异,一些变量需要改进(疫苗接种、排序)。所有27个国家都完成了调查表。大多数国家(23/27)报告说,该系统有效地监测了趋势,并认为它是有用和可以接受的(25/27),但只有16个国家认为它是及时的,14个国家认为它具有代表性。挑战包括基于案例的数据不足、数据链接问题和数据完整性不足。缓慢/低效的人工数据提取影响了时效性,而地理覆盖不足影响了代表性。多病原体监测被确定为主要优势,系统异质性被确定为主要弱点,医院信息系统的改进是主要机会,缺乏可持续资金是主要威胁。结论sari监测在监测趋势方面是有效的、有用的和可接受的。为了实现其他目标,提高时效性和代表性,我们建议改善数据完整性、数字化/自动化和地理覆盖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Eurosurveillance
Eurosurveillance INFECTIOUS DISEASES-
CiteScore
32.70
自引率
2.10%
发文量
430
审稿时长
3-8 weeks
期刊介绍: Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信